卫信康(603676) - 卫信康投资者关系活动记录表

Financial Performance - In the first three quarters of 2023, the company achieved a revenue of 1.061 billion yuan, a year-on-year decrease of 0.56% [3] - The net profit attributable to shareholders was 210 million yuan, reflecting a year-on-year increase of 39.24% [3] Business Strategy - The company adheres to the corporate spirit of "responsibility, sharing, credibility, and innovation" and aims to "care for life and maintain health" [3] - It focuses on R&D innovation, combining generic and innovative products to enhance its technological capabilities and expand into differentiated markets [3] Product Development - The company has recently approved a multi-vitamin injection (13) for intravenous use, aimed at preventing vitamin deficiencies in adults and children aged 11 and above [4] - The core products utilize an API+ formulation development model, with limited impact from raw material price fluctuations due to in-house production [3] Investor Engagement - The company expressed gratitude to investors for their trust and support during the Q3 earnings presentation [2] - The management team, including the chairman and independent directors, engaged in a Q&A session to address investor concerns and feedback [3][4]